BDBaris Emre Dayanc

Baris Emre Dayanc

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Baris Emre Dayanc has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Ali Osmay Gure

    Department of Medical Biology, Acibadem University, 34684 Istanbul, Turkey

    3 shared publications
  • Elizabeth A Repasky

    Department of Immunology, Roswell Park Cancer Institute , Buffalo, New York , USA

    2 shared publications
  • Elizabeth A. Repasky

    Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, USA

    2 shared publications
  • Erdal Birol Bostanci

    Department of Gastroenterological Surgery, Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey

    2 shared publications
  • Ismail Gomceli

    Department of Gastroenterological Surgery, Antalya Education and Research Hospital, Antalya, Turkey

    2 shared publications
  • Julie R. Ostberg

    Division of Cancer Immunotherapeutics and Tumor Immunology, City of Hope National Medical Center, Beckman Research Institute, Duarte, CA, USA

    2 shared publications

Latest Publications

  • Open Access

    Development of molecular subtype specific prognostic marker signature in immune response associated colon cancer through fuzzy based transcriptomic approach

    by Necla Koçhan, Barış Emre Dayanç

    Objective The molecular heterogeneity of colon cancer makes the prediction of disease prognosis challenging. In order to resolve this heterogeneity, molecular tumor subtyping present solutions. These approaches are expected to contribute to clinical decision-making. In this study, we aimed to identify Consensus Molecular Subtype (CMS) specific prognostic genes of colon cancer, focusing on anti-tumor immune-response associated CMS1, through a fuzzy-based machine learning approach. Materials and Methods We applied Fuzzy C-Means (FCM) clustering to stratify patients into two groups and identified genes that predict significant disease-specific survival difference between groups. We then performed Cox regression analyses to identify the most significant genes associated with disease-specific survival. A subtype-specific risk score and a final risk score formulae were constructed and used to calculate risk scores to stratify patients into low and high-risk groups within each CMS (1 to 4) or independent of CMS respectively. Results We identified CMS-specific genes and an overall 11-gene signature for prognostic risk prediction based on the disease-specific survival of colon cancer patients. The patients in both discovery and test cohorts were stratified into high and low-risk groups using subtype risk scores. The disease-specific survival of these risk groups within each CMS, except CMS3, was significantly different for both discovery and test cohorts. Discussion and Conclusions We have identified novel prognostic genes with potential immune regulatory roles within the immune-response associated CMS1. The low number of patients in the CMS3 cohort prevented subtype-specific prognostic gene validation. Tumor stage grouping of the validation cohort suggested the best prediction of prognosis in tumor stage III patients. In conclusion, newly identified eleven genes can efficiently predict the prognostic risk of colon cancer patients and classify patients into corresponding risk groups.

  • Open Access

    Classification of colon cancer patients into Consensus Molecular Subtypes using Support Vector Machines

    by Necla Kochan, Barıs Emre Dayanc

    Objective The molecular heterogeneity of colon cancer has made classification of tumors a requirement for effective treatment. One of the approaches for molecular subtyping of colon cancer patients is the Consensus Molecular Subtypes (CMS) developed by the Colorectal Cancer Subtyping Consortium (CRCSC). CMS-specific RNA-Seq dependent classification approaches are recent with relatively low sensitivity and specificity. In this study, we aimed to classify patients into CMS groups using RNA-seq profiles. Methods We first identified subtype specific and survival associated genes using Fuzzy C-Means (FCM) algorithm and log-rank test. Then we classified patients using Support Vector Machines with Backward Elimination methodology. Results We optimized RNA-seq based classification using 25 genes with minimum classification error rate. Here we report the classification performance using precision, sensitivity, specificity, false discovery rate and balanced accuracy metrics. Conclusion We present the gene list for colon cancer classification with minimum classification error rates. We observed the lowest sensitivity but highest specificity with CMS3-associated genes, which is significant due to low number of patients in the clinic for this group.


  • COVID-19 Pandemic Effect in Medical Education: “Izmir University of Economics Experience"

    by Incim Bezi̇rci̇oglu, Gönül Di̇nç Horasan, Yasemin Seval-Çeli̇k, Gül Güner Akdoğan, Mürvet Hayran, Sevinç İnan, İlgi Şemi̇n, Barış Emre DAYANÇ, Ayşe Banu DEMİR, Yusuf Hakan Abacioğlu

    Amaç: Bu çalışmada, 2019-20 eğitim yılı bahar yarıyılında İEÜTF tıp eğitiminde, COVID-19 pandemisinde uyarlanan yöntemleri/uygulamaları tanımlamak ve sonuçlarını tartışmak amaçlanmaktadır. Gereç ve Yöntem: Makalede İEÜTF tıp eğitimi tanıtılmış, pandemi nedeniyle eğitim programında yapılan değişiklikler, eğitimin nasıl yürütüldüğü ve değerlendirmesi konusundaki bilgiler paylaşılmıştır. Bulgular: İEÜTF pandemi öncesinde de eğitimde teknolojiyi yaygın kullanmakta olup, uzaktan eğitime neredeyse hiç ara vermeden başlayabilmiş, planlanan eğitsel etkinlikler gerçekleştirilmiştir. Bunda İEÜTF’de yalnızca ilk üç sınıfın eğitim görmesinin payı da büyüktür. Yüz yüze eğitimin zorunlu olduğu teknik ve klinik beceri uygulamaları ertelenmiştir. Sonuç: Halen yaşanan COVID-19 pandemi sürecinde tıp eğitiminde klinik eğitimlerin nasıl yürütüleceği konusunda stratejiler geliştirilmelidir. Yaşanan tüm bu sürecin, uzun vadede tıp eğitiminde değişikliğe neden olacağı düşünülmektedir.


  • Open Access

    A Combined ULBP2 and SEMA5A Expression Signature as a Prognostic and Predictive Biomarker for Colon Cancer

    by Secil Demirkol, Ismail Gomceli, Murat Isbilen, Baris Emre Dayanc, Mesut Tez, Erdal Birol Bostanci, Nesrin Turhan, Musa Akoglu, Ezgi Ozyerli, Sevi Durdu, et al.

    Background: Prognostic biomarkers for cancer have the power to change the course of disease if they add value beyond known prognostic factors, if they can help shape treatment protocols, and if they are reliable. The aim of this study was to identify such biomarkers for colon cancer and to understand the molecular mechanisms leading to prognostic stratifications based on these biomarkers.


  • Enhanced sensitivity of colon tumour cells to natural killer cell cytotoxicity after mild thermal stress is regulated through HSF1-mediated expression of MICA

    by Baris E. Dayanc, Sanjay Bansal, Ali Osmay Gure, Sandra O. Gollnick, Elizabeth A. Repasky

    Purpose: Previously we showed that mild thermal stress increased natural killer (NK) cell-mediated tumour cytotoxicity and that this could be blocked by anti-NKG2D or anti-MICA (major histolocompatability complex (MHC) class I related chain A) antibodies. Here, we investigated the role of the transcription factor heat shock factor 1 (HSF1) in thermal regulation of MICA expression in tumour cells in vitro and in vivo. Materials and methods: Hyperthermia experiments were conducted in vitro and in mice using a target temperature of 39.5 °C. Apoptotic cells and NK cells in situ were visualised by use of the TUNEL assay or expression of NKp46 respectively. Using Colo205 cells, HSF1 message was blocked utilising siRNA while luciferase reporter assays were used to measure the activity of the MICA promoter in vitro. Cell surface MICA was measured by flow cytometry. Results: Following whole body hyperthermia (WBH), tumour tissues showed an increase in NK cells and apoptosis. Mild thermal stress resulted in a transient increase in surface MICA and enhanced NK cytotoxicity of the Colo205 colon cancer cell line. Silencing (mRNA) HSF1 expression in Colo205 cells prevented the thermal enhancement of MICA message and surface protein levels, with partial loss of thermally enhanced NK cytotoxicity. Mutations of the HSF1 binding site on the MICA promoter implicated HSF1 in the thermal enhancement of MICA. Some, but not all, patient-derived colon tumour derived xenografts also exhibited an enhanced MICA message expression after WBH. Conclusions: Up-regulation of MICA expression in Colo205 cells and enhanced sensitivity to NK cell killing following mild thermal stress is dependent upon HSF1.


  • Synthesis, anticancer activities and molecular modeling studies of novel indole retinoid derivatives

    by A. Selen Gurkan-Alp, Mine Mumcuoglu, Cenk A. Andac, Emre Dayanc, Rengul Cetin-Atalay, Erdem Buyukbingol


  • Open Access

    Colon cancer associated transcript‐1: A novel RNA expressed in malignant and pre‐malignant human tissues

    by Aviram Nissan, Alexander Stojadinovic, Stella Mitrani‐Rosenbaum, David Halle, Ronit Grinbaum, Marina Roistacher, Andrea Bochem, Baris Emre Dayanc, Gerd Ritter, Ismail Gomceli, et al.

    Early detection of colorectal cancer (CRC) is currently based on fecal occult blood testing (FOBT) and colonoscopy, both which can significantly reduce CRC‐related mortality. However, FOBT has low‐sensitivity and specificity, whereas colonoscopy is labor‐ and cost‐intensive. Therefore, the discovery of novel biomarkers that can be used for improved CRC screening, diagnosis, staging and as targets for novel therapies is of utmost importance. To identify novel CRC biomarkers we utilized representational difference analysis (RDA) and characterized a colon cancer associated transcript (CCAT1), demonstrating consistently strong expression in adenocarcinoma of the colon, while being largely undetectable in normal human tissues (p < 000.1). CCAT1 levels in CRC are on average 235‐fold higher than those found in normal mucosa. Importantly, CCAT1 is strongly expressed in tissues representing the early phase of tumorigenesis: in adenomatous polyps and in tumor‐proximal colonic epithelium, as well as in later stages of the disease (liver metastasis, for example). In CRC‐associated lymph nodes, CCAT1 overexpression is detectable in all H&E positive, and 40.0% of H&E and immunohistochemistry negative lymph nodes, suggesting very high sensitivity. CCAT1 is also overexpressed in 40.0% of peripheral blood samples of patients with CRC but not in healthy controls. CCAT1 is therefore a highly specific and readily detectable marker for CRC and tumor‐associated tissues.